Improved Outcome for ALL by Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for Other Risk Groups.
Pieters R, de Groot-Kruseman H, Fiocco M, Verwer F, Van Overveld M, Sonneveld E, van der Velden V, Beverloo HB, Bierings M, Dors N, de Haas V, Hoogerbrugge P, Van der Sluis I, Tissing W, Veening M, Boer J, Den Boer M.
Pieters R, et al. Among authors: dors n.
J Clin Oncol. 2023 Sep 1;41(25):4130-4142. doi: 10.1200/JCO.22.02705. Epub 2023 Jul 17.
J Clin Oncol. 2023.
PMID: 37459571